HOME >> MEDICINE >> NEWS
Brief, high-dose steroid treatment offers extended relief to giant cell arteritis patients

ATLANTA -- A new study offers both hope and a practical treatment option for patients with giant cell arteritis (GCA). Researchers from Emory University and the Mayo Clinic have found that by treating newly diagnosed GCA patients with just three days of a high-dose intravenous steroid, patients relapsed less in the following year and were able to significantly taper off usage of an oral steroid. The study is published in the October issue of the journal Arthritis & Rheumatism.

Giant cell arteritis is characterized by inflammation of arteries, primarily in the head, and affects 20 out of every 100,000 people. GCA inflammation may lead to swelling and headaches, or, as it progresses, vision loss, strokes and aortic aneurysms. While past research has shown a genetic link to the disease, which primarily affects Caucasian women over the age of 50, there is no known cause or cure.

For the last 40 years, physicians have been able to treat and reverse some symptoms of GCA by prescribing prednisone, to be taken daily over a year or more. "Patients improve promptly and reliably, within days of when we treat them," says Cornelia M. Weyand, MD, PhD, co-director of the Kathleen B. and Mason I. Lowance Center for Human Immunology at Emory University and an author of the paper. "The problem is that patients have to take prednisone for a long time and in high doses, and they are at risk of developing side effects." Common side effects include hypertension, diabetes and osteoporosis.

While scientists have attempted to develop new drugs that would be more effective and have fewer side effects, their results have been unsuccessful. "We and others tried to look into other types of treatments that could help with this disease," says Jrg Goronzy, MD, PhD, senior author of the paper, and co-director of the Lowance Center.

"Even the modern and effective immunosuppressants do not improve the situation with these patients," says Dr. Weyan
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
2-Oct-2006


Page: 1 2

Related medicine news :

1. Study examines characteristics of female high school students who report steroid use
2. Female teen steroid use not limited to athletes
3. Bronchial thermoplasty may allow severe asthma patients to wean off oral corticosteroids
4. Inhaled steroids may not be enough for some children with asthma
5. Nonsteroidal anti-inflammatory drugs use associated with higher gastrointestinal complications
6. Short-term topical corticosteroid use may offer relief for patients with acute form of psoriasis
7. Pre-clinical study suggests how steroid can reverse post-traumatic stress
8. Inhaled corticosteroids reduce death in patients with COPD
9. Non-steroidal anti-inflammatory drugs (NSAIDs) and congenital anomalies
10. National trial gives unprecedented support for steroid withdrawal in kidney transplants
11. New study adds weight to argument for steroid injections in patients with hip osteoarthritis

Post Your Comments:
(Date:3/6/2015)... Follow us on LinkedIn – ... drug refers to testing of absorption, distribution, metabolism, and ... toxicity studies are clubbed together with ADME, it is ... on lowering costs and time during drug development are ... drug development model uses toxicity and efficacy testing in ...
(Date:3/6/2015)... USA (PRWEB) March 06, 2015 Parents ... the fatal reality of substance use disorders. School programs ... to be marginally successful. NOPE, or Narcotics Overdose Prevention ... nationwide, according to Healthline News on Feb. ... illicit and prescription opiate drugs, drug prevention proponents are ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
(Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
(Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
(Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
(Date:3/5/2015)... 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ) ... ended January 3, 2015.  , Revenues were $11.8 ... the Company and up 11% from $10.6 million in the ... a record, up 12% from $38.3 million in 2013. ... up from 48.6% in the fourth quarter of the prior ...
Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
Cached News: